Her2 Expression and Response of Breast Cancer to Adjuvant Chemotherapy

Alinta Hegmane; Uldis Vikmanis

doi:10.2478/v10046-008-0023-0

.blurhash-client-img { display: none !important; }

Her2 Expression and Response of Breast Cancer to Adjuvant Chemotherapy

Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.

Volume 62 (2008): Issue 3 (June 2008)

By: Alinta Hegmane and Uldis Vikmanis

Open Access

|Nov 2008

Anonymous (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on reccurrence and 15-year survival: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), 365 (9472), 1687-1717.
Search in Google Scholar
De Laurentiis, M., Caputo, F., Massarelli, E., Forestieri, V., Vernaglia, A., Carlomagno, C., Lauria, R., Bianco, A. R., De Placido, S. (2001). HER2 expression and anthracycline effect: Results from the Naple GUN 3 randomized trial., 20, 34A (abstract 133).
Search in Google Scholar
Dressler, L. G., Berry, D. A., Broadwater, G., Cowan, D., Cox, K., Griffin, S., Miller, A., Tse, J., Novotny, D., Persons, D. L., Barcos, M., Henderson, I. C., Liu, E. T., Thor, A., Budman, D., Muss, H., Norton, L., Hayes, D. F. (2005). Comparison of HER2 status by fluorescencehybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients., 23(19), 4287-4297.
Open DOI Search in Google Scholar
Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Save-Soderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., Reed, R. (1992). Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group., 10(7), 1049-1056.
Search in Google Scholar
Harris, L. N., Yang, L., Liotcheva, V., Pauli, S., Iglehart, J. D., Colvin, O. M., Hsieh, T. S. (2001). Induction of topoisomerase II activity after Erb B2 activation is associated with a differential response to breast cancer chemotherapy., 7(6), 1497-1504.
Search in Google Scholar
Jarvinen, T. A., Liu, E. T. (2003). HER-2/neu and topoisomerase IIalpha in breast cancer., 78(3), 299-311.
Open DOI Search in Google Scholar
Jarvinen, T. A. H., Tanner, M., Rantonen, V., Barlund, M., Borg, A., Grénman, S., Isola, J. (2000). Amplification and deletion of topoisomerase II associate with Erb B-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer., 156(3), 839-847.
Open DOI Search in Google Scholar
Knoop, A. S., Knudsen, H., Balslev, E., Rasmussen, B. B., Overgaard, J., Nielsen, K. V., Schonau, A., Gunnarsdottir, K., Olsen, K. E., Mouridsen, H., Ejlertsen, B. (2005). Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil., 23(30), 7483-7490.
Open DOI Search in Google Scholar
Konecny, G., Fritz, M., Untch, M., Lebeau, A., Felber, M., Lude, S., Beryt, M., Hepp, H., Slamon, D., Pegram, M. (2001). HER-2/neu overexpression andchemosensitivity to CMF and FEC in primary breast cancer., 69(1), 53-63.
Open DOI Search in Google Scholar
Levine, M. N., Bramwell, H., Pritchard, K. I., Shepherd, L. E., Tu, D., Paul, N. (1998). Randomised trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer., 16(22), 2651-2658.
Open DOI Search in Google Scholar
Paik, S., Bryant, J., Park, C., Fisher, B., Tan-Chiu, E., Hyams, D., Fisher, E. R., Lippman, M. E., Wickerham, D. L., Wolmark, N. (1998). erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer., 90(18), 1361-1370.
Open DOI Search in Google Scholar
Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J., Slamon, D. J. (1997). The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells., 15(5), 537-547.
Open DOI Search in Google Scholar
Pinder, M. C., Duan, Z., Goodwin, J. S., Hortobagyi, G. N., Giordano, S. H. (2007). Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer., 25(25), 3808-3815.
Open DOI Search in Google Scholar
Pritchard, K. I., Shepherd, L. E., O'Malley, F. P., Andrulis, I. L., Tu, D., Bramwell, V. H., Levine, M. N. (2006). HER2 and responsiveness of breast cancer to adjuvant chemotherapy., 354(20), 2103-2111.
Open DOI Search in Google Scholar
Slamon, D. J., Godolphin, W., Jones, J. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., Press, M. F. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer., 244(4905), 707-712.
Search in Google Scholar
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Lager, A., McShane, L. M., Paik, S., Pegram, M. D., Perez, E. A., Press, M. F., Rhodes, A., Sturgeon, C., Taube, S. E., Tubbs, R., Vance, G. H., van de Vijver, M., Wheeler, T. M., Hayes, D. F. (2007). American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer., 25(1), 118-145.
Open DOI Search in Google Scholar